Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences

Waranugraha, Yoga; Rizal, Ardian; Syaban, Mokhamad Fahmi Rizki; Faratisha, Icha Farihah Deniyati; Erwan, Nabila Erina; Yunita, Khadijah Cahya

doi:10.1186/s43044-021-00194-1

The Egyptian Heart Journal

Table 2 Summary of the outcomes of interest

From: Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences

Outcomes	NOACs (n)	Warfarin (n)	Model	HR	95% CI		p value of heterogeneity	p value of Begg’s test	p value of Egger’s test	p
Outcomes	NOACs (n)	Warfarin (n)	Model	HR	Lower limit	Upper limit	p value of heterogeneity	p value of Begg’s test	p value of Egger’s test	p
Stroke
Apixaban	256909	474732	Random	0.73	0.64	0.84	< 0.01	0.77	0.77	< 0.01
Dabigatran	345545	365144	Random	0.87	0.81	0.94	< 0.01	0.70	0.78	< 0.01
Edoxaban	46035	78185	Fixed	0.67	0.60	0.76	0.84	1.00	0.46	< 0.01
Rivaroxaban	336406	486587	Random	0.81	0.73	0.90	< 0.01	0.19	0.41	< 0.01
All NOACs	984895	1604648	Random	0.77	0.69	0.87	< 0.01	0.73	0.85	< 0.01
All-cause mortality
Apixaban	95097	309813	Random	0.69	0.49	0.98	< 0.01	1.00	0.60	0.04
Dabigatran	216235	390118	Random	0.67	0.57	0.80	< 0.01	0.35	0.06	< 0.01
Edoxaban	16210	16785	Random	0.52	0.31	0.85	0.02	1.00	0.53	0.01
Rivaroxaban	128600	310114	Random	0.91	0.70	1.18	< 0.01	0.76	0.89	0.47
All NOACs	456142	1026830	Fixed	0.71	0.63	0.81	0.14	0.31	0.08	< 0.01
Major bleeding
Apixaban	234818	314596	Random	0.57	0.53	0.63	< 0.01	0.42	0.20	< 0.01
Dabigatran	292539	382810	Random	0.75	0.67	0.83	< 0.01	0.27	0.15	< 0.01
Edoxaban	48875	81025	Random	0.55	0.45	0.66	0.09	0.71	0.27	< 0.01
Rivaroxaban	337030	377026	Random	0.90	0.82	0.98	< 0.01	0.38	0.06	0.01
All NOACs	913262	1155457	Random	0.68	0.54	0.86	< 0.01	0.73	0.63	< 0.01
Intracranial bleeding
Apixaban	251901	442439	Random	0.57	0.48	0.68	< 0.01	0.71	0.06	< 0.01
Dabigatran	323015	488790	Random	0.44	0.38	0.52	< 0.01	1.00	0.14	< 0.01
Edoxaban	48875	81025	Random	0.44	0.26	0.76	< 0.01	1.00	0.06	< 0.01
Rivaroxaban	326289	439920	Fixed	0.69	0.64	0.74	0.14	0.08	0.07	< 0.01
All NOACs	950080	1452174	Random	0.54	0.42	0.70	< 0.01	0.73	0.26	< 0.01
Gastrointestinal bleeding
Apixaban	242813	401123	Random	0.58	0.51	0.67	< 0.01	0.43	0.07	< 0.01
Dabigatran	326750	490358	Random	0.99	0.87	1.12	< 0.01	0.08	0.06	0.88
Edoxaban	48875	81025	Random	0.62	0.44	0.87	< 0.01	1.00	0.09	< 0.01
Rivaroxaban	312311	396000	Random	1.00	0.86	1.17	< 0.01	0.58	0.06	0.97
All NOACs	930749	1368506	Random	0.78	0.58	1.06	< 0.01	0.73	0.75	0.12

CI = confidence interval, HR = hazard ratio, NOACs = non-vitamin K antagonist oral anticoagulants

Back to article page